Denali Therapeutics (DNLI) Accumulated Depreciation & Amortization (2017 - 2024)
Historic Accumulated Depreciation & Amortization for Denali Therapeutics (DNLI) over the last 8 years, with Q4 2024 value amounting to $7.8 million.
- Denali Therapeutics' Accumulated Depreciation & Amortization fell 5336.6% to $7.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $7.8 million, marking a year-over-year decrease of 5336.6%. This contributed to the annual value of $7.8 million for FY2024, which is 5336.6% down from last year.
- Per Denali Therapeutics' latest filing, its Accumulated Depreciation & Amortization stood at $7.8 million for Q4 2024, which was down 5336.6% from $16.7 million recorded in Q4 2023.
- In the past 5 years, Denali Therapeutics' Accumulated Depreciation & Amortization ranged from a high of $16.7 million in Q4 2023 and a low of $7.8 million during Q4 2024
- Over the past 5 years, Denali Therapeutics' median Accumulated Depreciation & Amortization value was $8.6 million (recorded in 2021), while the average stood at $10.4 million.
- In the last 5 years, Denali Therapeutics' Accumulated Depreciation & Amortization skyrocketed by 6082.69% in 2023 and then crashed by 5336.6% in 2024.
- Over the past 5 years, Denali Therapeutics' Accumulated Depreciation & Amortization (Quarter) stood at $8.5 million in 2020, then increased by 0.81% to $8.6 million in 2021, then increased by 20.93% to $10.4 million in 2022, then surged by 60.83% to $16.7 million in 2023, then crashed by 53.37% to $7.8 million in 2024.
- Its last three reported values are $7.8 million in Q4 2024, $16.7 million for Q4 2023, and $10.4 million during Q4 2022.